Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

T2 Biosystems stock

TTOO
US89853L1044
A119H3

Price

1.82
Today +/-
+0
Today %
+0 %
P

T2 Biosystems stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the T2 Biosystems stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the T2 Biosystems stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the T2 Biosystems stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze T2 Biosystems's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

T2 Biosystems Stock Price History

DateT2 Biosystems Price
10/4/20241.82 undefined
10/3/20241.82 undefined
10/2/20241.88 undefined
10/1/20241.86 undefined
9/30/20241.97 undefined
9/27/20242.00 undefined
9/26/20241.98 undefined
9/25/20242.01 undefined
9/24/20242.05 undefined
9/23/20242.06 undefined
9/20/20242.19 undefined
9/19/20242.20 undefined
9/18/20242.15 undefined
9/17/20242.25 undefined
9/16/20242.31 undefined
9/13/20242.53 undefined
9/12/20242.39 undefined
9/11/20242.30 undefined
9/10/20242.50 undefined
9/9/20242.68 undefined
9/6/20242.95 undefined

T2 Biosystems Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into T2 Biosystems, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by T2 Biosystems from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects T2 Biosystems’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of T2 Biosystems. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into T2 Biosystems’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing T2 Biosystems’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on T2 Biosystems’s growth potential.

T2 Biosystems Revenue, EBIT and net profit per share

DateT2 Biosystems RevenueT2 Biosystems EBITT2 Biosystems Net Income
2029e80.07 M undefined0 undefined-3.92 M undefined
2028e62.22 M undefined-33.76 M undefined-6.6 M undefined
2027e47.12 M undefined-41.62 M undefined-9.98 M undefined
2026e33.97 M undefined-38.05 M undefined-12.48 M undefined
2025e23.56 M undefined-39.58 M undefined-21.22 M undefined
2024e10.81 M undefined-42.23 M undefined-55.27 M undefined
20237.19 M undefined-47.15 M undefined-50.08 M undefined
202222.31 M undefined-55.2 M undefined-62.33 M undefined
202128.06 M undefined-42.97 M undefined-49.24 M undefined
202018.13 M undefined-40.26 M undefined-46.8 M undefined
20198.34 M undefined-52.06 M undefined-59.01 M undefined
201810.5 M undefined-45.09 M undefined-51.15 M undefined
20174.67 M undefined-53.85 M undefined-62.43 M undefined
20164.08 M undefined-50.88 M undefined-54.8 M undefined
20152.81 M undefined-43.38 M undefined-45.29 M undefined
2014120,000 undefined-30.68 M undefined-35.96 M undefined
2013270,000 undefined-19.69 M undefined-27.52 M undefined
201220,000 undefined-14.65 M undefined-18.87 M undefined

T2 Biosystems Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0002441081828227102333476280
----100.00-150.00-20.00125.0055.56-21.43-68.1842.86130.0043.4842.4231.9129.03
---50.00-50.00-175.00-40.00-100.00-11.1125.004.55-114.29------
0001-2-7-4-8-271-8000000
-14-19-30-43-50-53-45-52-40-42-55-47-42-39-38-41-330
----2,150.00-1,250.00-1,325.00-450.00-650.00-222.22-150.00-250.00-671.43-420.00-169.57-115.15-87.23-53.23-
-18-27-35-45-54-62-51-59-46-49-62-50-55-21-12-9-6-3
-50.0029.6328.5720.0014.81-17.7415.69-22.036.5226.53-19.3510.00-61.82-42.86-25.00-33.33-50.00
00000.010.010.010.010.020.030.052.61000000
------------------
Details

Keystats

ⓘ

Revenue and Growth

The T2 Biosystems Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the T2 Biosystems is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201220132014201520162017201820192020202120222023
                       
9.7130.273.8573.6673.4941.850.8111.0342.1932.2410.3315.69
000.20.370.330.471.792.835.15.132.161.42
000000000000
000.120.680.81.342.683.63.643.914.294.82
0.140.21.160.840.820.711.341.442.663.112.583.26
9.8530.475.3375.5575.4444.3256.6218.953.5944.3919.3625.19
1.21.122.7610.6613.5910.027.329.2114.8114.4413.279.05
0000000010000
000000000000
000000000000
000000000000
0.390.371.050.620.540.530.390.390.691.71.690.56
1.591.493.8111.2814.1310.557.719.625.516.1414.969.61
11.4431.8979.1486.8389.5754.8764.3328.579.0960.5334.3234.8
                       
66.14112.810.020.020.030.040.040.050.150.170.010
00156.58195.8243267.42328.51342.12431.54459.15494.56556.26
-62.66-89.55-103.6-148.89-203.69-266.12-317.17-376.18-422.98-472.22-534.22-584.3
0000000010000
000000000000
3.4823.265346.9339.341.3411.38-34.018.72-12.9-39.65-28.04
0.570.940.741.230.960.650.743.752.062.831.31.53
0.731.323.664.164.916.226.0711.217.518.348.6211.33
0.010.030.482.412.754.223.112.710.230.520.212.01
0000000000041.28
0.821.760.34.451.2740.742.3742.90000
2.134.055.1812.259.8951.7952.2960.579.811.6910.1356.15
5.063.320.6626.1239.51.010045.2447.7949.650
000000000000
0.771.270.31.510.840.730.631.9215.3213.9614.26.68
5.834.5720.9627.6340.341.740.631.9260.5661.7563.856.68
7.968.6226.1439.8850.2353.5352.9262.4970.3673.4473.9862.83
11.4431.8879.1486.8189.5754.8764.328.4879.0860.5434.3334.8
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of T2 Biosystems provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand T2 Biosystems's financial health and stability.

Assets

T2 Biosystems's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that T2 Biosystems must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of T2 Biosystems after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into T2 Biosystems's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (k)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20122013201420152016201720182019202020212022
-14-20-31-45-54-62-51-59-46-49-62
00012222111
00000000000
0001,00000-3,0001,000-6,000-2,0000
013810162215121817
00012334333
00000000000
-13-18-28-37-46-47-40-45-43-38-50
00-2-7-5-200000
00-2-7-5-200-36249
00000000-352510
00000000000
4015911-1-10000
0395835111002029
43873455118496852029
000039184968500
00000000000
-9204300-318-3966-11
-13.58-18.56-30.26-45.44-51.93-50.2-40.73-46.12-44.02-39.33-50.97
00000000000

T2 Biosystems stock margins

The T2 Biosystems margin analysis displays the gross margin, EBIT margin, as well as the profit margin of T2 Biosystems. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for T2 Biosystems.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the T2 Biosystems's sales revenue. A higher gross margin percentage indicates that the T2 Biosystems retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the T2 Biosystems's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the T2 Biosystems's total revenue generated. When comparing the revenue margin year over year, investors can gauge the T2 Biosystems's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the T2 Biosystems. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the T2 Biosystems's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

T2 Biosystems Margin History

T2 Biosystems Gross marginT2 Biosystems Profit marginT2 Biosystems EBIT marginT2 Biosystems Profit margin
2029e-113.58 %0 %-4.9 %
2028e-113.58 %-54.26 %-10.6 %
2027e-113.58 %-88.31 %-21.19 %
2026e-113.58 %-112.01 %-36.74 %
2025e-113.58 %-167.97 %-90.05 %
2024e-113.58 %-390.57 %-511.21 %
2023-113.58 %-655.54 %-696.19 %
20225.38 %-247.42 %-279.38 %
202126.23 %-153.14 %-175.48 %
2020-14.07 %-222.06 %-258.14 %
2019-101.08 %-624.22 %-707.55 %
2018-46.67 %-429.43 %-487.14 %
2017-157.6 %-1,153.1 %-1,336.83 %
2016-68.38 %-1,247.06 %-1,343.14 %
201538.08 %-1,543.77 %-1,611.74 %
2014-113.58 %-25,566.67 %-29,966.67 %
2013-113.58 %-7,292.59 %-10,192.59 %
2012-113.58 %-73,250 %-94,350.01 %

T2 Biosystems Stock Sales Revenue, EBIT, Earnings per Share

The T2 Biosystems earnings per share therefore indicates how much revenue T2 Biosystems has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue T2 Biosystems earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates T2 Biosystems's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of T2 Biosystems’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating T2 Biosystems's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

T2 Biosystems Revenue, EBIT and net profit per share

DateT2 Biosystems Sales per ShareT2 Biosystems EBIT per shareT2 Biosystems Earnings per Share
2029e4.58 undefined0 undefined-0.22 undefined
2028e3.56 undefined0 undefined-0.38 undefined
2027e2.7 undefined0 undefined-0.57 undefined
2026e1.94 undefined0 undefined-0.71 undefined
2025e1.35 undefined0 undefined-1.21 undefined
2024e0.62 undefined0 undefined-3.16 undefined
20232.76 undefined-18.07 undefined-19.19 undefined
2022446.2 undefined-1,104 undefined-1,246.6 undefined
2021935.33 undefined-1,432.33 undefined-1,641.33 undefined
2020906.5 undefined-2,013 undefined-2,340 undefined
2019834 undefined-5,206 undefined-5,901 undefined
20181,050 undefined-4,509 undefined-5,115 undefined
2017467 undefined-5,385 undefined-6,243 undefined
2016408 undefined-5,088 undefined-5,480 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined

T2 Biosystems business model

T2 Biosystems Inc. is an American company that was founded in 2006. The company is based in Lexington, Massachusetts. The founders of T2 Biosystems aimed to create an innovative diagnostic system that could improve hospital performance. Their business model is based on the development, manufacturing, and distribution of innovative instruments and diagnostic solutions. T2 Biosystems operates in various sectors, with a focus on diagnosis and healthcare solutions. The key areas are: 1. Infectious diseases: T2 Biosystems develops systems that enable rapid and accurate diagnosis of infectious diseases in hospitals and other medical facilities. The team has already made significant progress in detecting infections such as sepsis, pneumonia, and other diseases that require prompt diagnosis to increase patient survival rates. 2. Hematology: The company has also developed a product called T2HemoStat, which improves accuracy in determining biomarkers in blood samples. HemoStat allows for real-time analysis of patient samples to achieve faster results than current standard tests. 3. Healthcare: T2 Biosystems also offers solutions to improve healthcare. The goal is to address issues in healthcare by using data and information more intelligently. The company is working on products tailored to the needs of hospitals and healthcare providers. T2 Biosystems pursues a collaborative strategy, fostering cooperation among clinics, customers, and companies. T2 Biosystems has successfully launched several products, including the T2Dx instrument, which enables rapid and accurate detection of infections. The measurement system is based on T2 Magnetic Resonance (T2MR) technology, which can identify cells and biomolecules based on magnetic resonance. The T2Dx system is also capable of identifying drugs directly in the tests, allowing for better utilization of antibiotics to combat resistant bacteria. In collaboration with Harvard Medical School, the company is also working on developing specific tests focused on the detection of bacteria or viruses. The team at T2 Biosystems has developed an innovative system that allows for the analysis of bacterial or viral strains. T2 Biosystems has a rapidly growing customer base and is a key player in the healthcare market. The company has already established important partnerships with some of the leading hospitals in the US and continues to work on forming further partnerships in other parts of the world. The products of T2 Biosystems have received numerous awards, including the "Best of Show" prize at the Association of Clinical Chemistry Annual Meeting and the "Medical Device Excellence Award" from the Massachusetts Medical Device Industry Council. The company operates in a highly competitive market. To remain competitive, T2 Biosystems heavily invests in research and development. The company also has a strong presence on social media to raise awareness of their products and services. T2 Biosystems aims to achieve further medical advancements and develop innovative technologies to improve patient care in the future. T2 Biosystems is one of the most popular companies on Eulerpool.com.

T2 Biosystems Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

T2 Biosystems Revenue by Segment

Segmente2021202020192018
Product16.65 M USD11.68 M USD5.33 M USD4.81 M USD
Contribution11.41 M USD6.44 M USD2.45 M USD-
Research service-11,000 USD563,000 USD5.7 M USD
Instrument rentals--184,000 USD-
Product, consumables14.51 M USD8.42 M USD2.86 M USD2.39 M USD
Contribution revenue11.41 M USD6.44 M USD2.45 M USD-
Product, instruments2.06 M USD3.14 M USD2.28 M USD1.9 M USD
Instrument rentals71,000 USD115,000 USD-523,000 USD

T2 Biosystems Revenue by Region

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

T2 Biosystems Revenue by Segment

DateOther Countries
20212.3 M USD
20202 M USD
20192.8 M USD
20182.2 M USD

T2 Biosystems SWOT Analysis

Strengths

T2 Biosystems Inc has several key strengths that contribute to its success in the market. Firstly, the company has developed innovative diagnostic technologies that greatly improve the accuracy and speed of detecting infectious diseases. This gives T2 Biosystems a competitive advantage over traditional testing methods. Secondly, T2 Biosystems has established strategic partnerships with renowned healthcare organizations and major pharmaceutical companies. These partnerships not only provide access to a wider customer base but also enhance the company's credibility and reputation in the industry. Another strength of T2 Biosystems is its robust intellectual property portfolio. The company holds multiple patents related to its diagnostic technologies, ensuring protection against potential competitors and securing long-term revenue streams. Lastly, T2 Biosystems possesses a talented team of scientists and researchers who continuously drive innovation within the organization. Their expertise and dedication enable the company to stay at the forefront of diagnostic technology development.

Weaknesses

Despite its strengths, T2 Biosystems also faces certain weaknesses that need to be addressed. One key weakness is the company's dependence on a limited product portfolio. Currently, T2 Biosystems primarily focuses on infectious disease diagnostics, which leaves it vulnerable to changes in market demand or the emergence of competitors with broader diagnostic offerings. Moreover, T2 Biosystems operates in a highly regulated industry, where obtaining necessary approvals and clearances for its products can be time-consuming and costly. This can result in delays in product launches and revenue generation. Additionally, the company's geographical reach is somewhat limited. T2 Biosystems primarily operates in the United States, with relatively limited global presence. Expanding into new international markets could be a significant challenge that needs to be carefully considered.

Opportunities

T2 Biosystems has several opportunities to capitalize on in the future. Firstly, there is a growing demand for rapid and accurate diagnostic solutions, especially in the healthcare industry. T2 Biosystems can leverage its innovative technologies to tap into this expanding market and gain a larger market share. Additionally, the increasing focus on personalized medicine offers potential opportunities for T2 Biosystems. By developing diagnostic solutions that cater to individual patient needs and genetic profiles, the company can differentiate itself from competitors and provide unique value to healthcare providers. Furthermore, T2 Biosystems can explore partnerships and collaborations with pharmaceutical companies to develop companion diagnostics. This would involve creating diagnostic tests that can determine the most effective treatment options based on an individual's genetic makeup, potentially revolutionizing the field of precision medicine.

Threats

T2 Biosystems faces certain threats that could impact its growth and profitability. One significant threat is the intense competition within the diagnostic industry. Established players and emerging startups are constantly striving to develop and market innovative diagnostic solutions, making it crucial for T2 Biosystems to stay ahead of the curve and continuously innovate. Another threat stems from the potential regulatory and reimbursement changes. Changes in government regulations or reimbursement policies could impact the adoption and usage of T2 Biosystems' products, potentially hindering the company's revenue growth. Additionally, the rapid advancement of technology poses a threat to T2 Biosystems. Emerging technologies and new diagnostic platforms could potentially render the company's current offerings obsolete if it fails to keep up with industry trends and maintain its competitive edge.

T2 Biosystems Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

T2 Biosystems historical P/E ratio, EBIT multiple, and P/S ratio

T2 Biosystems shares outstanding

The number of shares was T2 Biosystems in 2023 — This indicates how many shares 2.61 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue T2 Biosystems earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates T2 Biosystems's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of T2 Biosystems’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating T2 Biosystems's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

T2 Biosystems stock splits

In T2 Biosystems's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for T2 Biosystems.

T2 Biosystems latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.99 -0.66  (33.29 %)2024 Q2
3/31/2024-1.9 -2.66  (-40.21 %)2024 Q1
9/30/2023-3.93 -3.45  (12.15 %)2023 Q3
6/30/2023-27.2 -8  (70.59 %)2023 Q2
3/31/2023-122.74 -132  (-7.54 %)2023 Q1
12/31/2022-173.91 -141  (18.92 %)2022 Q4
9/30/2022-208.42 -295  (-41.54 %)2022 Q3
6/30/2022-459 -500  (-8.93 %)2022 Q2
3/31/2022-382.5 -500  (-30.72 %)2022 Q1
12/31/2021-459 -350  (23.75 %)2021 Q4
1
2
3
4

Eulerpool ESG Scorecard© for the T2 Biosystems stock

Eulerpool World ESG Rating (EESG©)

22/ 100

🌱 Environment

7

👫 Social

24

🏛️ Governance

34

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

T2 Biosystems shareholders

%
Name
Stocks
Change
Date
23.48305 % CR Group4,104,8383,280,6184/12/2024
2.00229 % New Dimensions Trading, Ltd.350,000350,0002/20/2024
0.31467 % Susquehanna International Group, LLP55,00451,87112/31/2023
0.26141 % The Vanguard Group, Inc.45,695-13,12712/31/2023
0.21145 % BlackRock Institutional Trust Company, N.A.36,961-212/31/2023
0.13761 % Geode Capital Management, L.L.C.24,054-312/31/2023
0.11769 % GSA Capital Partners LLP20,572-5,22412/31/2023
0.11653 % The Lind Partners, LLC20,37010,18512/31/2023
0.11442 % Carrick (Jason)20,00020,0006/15/2023
0.08820 % Jane Street Capital, L.L.C.15,4178,94812/31/2023
1
2
3
4
5
...
10

T2 Biosystems Executives and Management Board

Mr. John Sperzel59
T2 Biosystems Chairman of the Board, President, Chief Executive Officer (since 2020)
Compensation 1.99 M
Mr. Michael Gibbs52
T2 Biosystems Senior Vice President, General Counsel
Compensation 767,293
Mr. John Sprague64
T2 Biosystems Chief Financial Officer
Compensation 762,293
Mr. John Cumming77
T2 Biosystems Lead Independent Director
Compensation 106,400
Mr. David Elsbree73
T2 Biosystems Independent Director
Compensation 69,200
1
2
3

T2 Biosystems Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
HCA Healthcare Stock
HCA Healthcare
SupplierCustomer0,790,530,680,59-0,13-0,61
Advanced Technology Stock
Advanced Technology
SupplierCustomer0,710,750,620,590,49-
AbbVie Stock
AbbVie
SupplierCustomer0,370,740,21-0,43-0,75-0,63
General Electric Stock
General Electric
SupplierCustomer0,240,750,730,600,77-0,25
Canon Stock
Canon
SupplierCustomer-0,53-0,94-0,45-0,58-0,68-0,59
Eurobio-Scientific Stock
Eurobio-Scientific
SupplierCustomer-0,68-0,760,340,45-0,50-0,28
AddLife B Stock
AddLife B
SupplierCustomer-0,740,170,750,620,39-0,54
1

Most common questions regarding T2 Biosystems

What values and corporate philosophy does T2 Biosystems represent?

T2 Biosystems Inc represents a set of core values and a corporate philosophy that drives its operations. The company focuses on innovation, leveraging cutting-edge technology to revolutionize diagnostics. T2 Biosystems Inc is committed to improving patient outcomes by providing faster and more accurate diagnostic solutions. With a strong emphasis on collaboration, T2 Biosystems Inc actively engages with healthcare professionals and partners to develop impactful solutions. The company's dedication to excellence, integrity, and efficiency reflects its commitment to delivering value to patients, healthcare providers, and stakeholders. T2 Biosystems Inc continually strives to advance healthcare through breakthrough innovations and a patient-centric approach.

In which countries and regions is T2 Biosystems primarily present?

T2 Biosystems Inc is primarily present in the United States and Europe.

What significant milestones has the company T2 Biosystems achieved?

T2 Biosystems Inc, a leading biotechnology company, has achieved several significant milestones. Firstly, the company developed and received FDA clearance for the T2Dx® Instrument, allowing rapid and accurate identification of deadly pathogens directly from whole blood. Furthermore, T2 Biosystems successfully launched their T2Bacteria® and T2Candida® Panels, revolutionizing the diagnosis of bloodstream infections. Additionally, the company secured numerous strategic partnerships and collaborations to expand the reach of their innovative technologies. With these achievements, T2 Biosystems Inc continues to make remarkable progress in improving patient outcomes by providing faster and more precise diagnostic solutions.

What is the history and background of the company T2 Biosystems?

T2 Biosystems Inc is a leading diagnostic company specializing in the development and commercialization of innovative technologies. Founded in 2006, T2 Biosystems has been revolutionizing the medical industry by providing rapid and accurate diagnostic solutions. The company focuses on the detection of pathogens and other critical conditions, aiming to improve patient outcomes and save lives. With its unique T2 Magnetic Resonance (T2MR) technology, T2 Biosystems has gained recognition as a pioneer in the field of diagnostics. T2 Biosystems Inc continues to drive advancements in diagnostic testing and is committed to delivering reliable results for healthcare professionals globally.

Who are the main competitors of T2 Biosystems in the market?

The main competitors of T2 Biosystems Inc in the market are bioMérieux SA, Bio-Rad Laboratories Inc, Thermo Fisher Scientific Inc, and Bruker Corporation.

In which industries is T2 Biosystems primarily active?

T2 Biosystems Inc is primarily active in the healthcare and medical technology industries.

What is the business model of T2 Biosystems?

The business model of T2 Biosystems Inc is centered around developing and commercializing innovative medical diagnostic products. The company focuses on creating breakthrough solutions for the detection of severe infections, such as bloodstream infections, that can lead to life-threatening conditions. T2 Biosystems utilizes its proprietary T2 Magnetic Resonance (T2MR®) technology, which enables rapid and accurate detection of pathogens directly from a patient's whole blood sample. This technology eliminates the need for time-consuming culture-based methods, offering healthcare providers timely and actionable results. By applying cutting-edge molecular diagnostics to improve patient outcomes, T2 Biosystems Inc has established itself as a leader in the field of infectious disease diagnostics.

What is the P/E ratio of T2 Biosystems 2024?

The T2 Biosystems P/E ratio is -0.09.

What is the P/S ratio of T2 Biosystems 2024?

The T2 Biosystems P/S ratio is 0.44.

What is the AlleAktien quality score of T2 Biosystems?

The AlleAktien quality score for T2 Biosystems is 8/10.

What is the revenue of T2 Biosystems 2024?

The expected T2 Biosystems revenue is 10.81 M USD.

How high is the profit of T2 Biosystems 2024?

The expected T2 Biosystems profit is -55.27 M USD.

What is the business model of T2 Biosystems

T2 Biosystems Inc. is a biotechnology company specializing in the development and commercialization of diagnostic solutions. The company is based in Lexington, Massachusetts, USA, and offers a comprehensive portfolio of products and services. T2 Biosystems' business model is focused on three main areas: diagnostics, research and development, and clinical trials. The company aims to improve and expedite diagnostics in the areas of infectious diseases and sepsis. The flagship product of T2 Biosystems is the T2 Magnetic Resonance (T2MR) technology, an innovative method for rapid and accurate diagnosis of infections. This approach uses magnetic resonance technologies to detect pathogens directly in blood samples. Unlike traditional tests, T2MR technology can identify infections in less than six hours, leading to faster and more targeted treatment. Other products of T2 Biosystems include T2Candida, a blood test for the diagnosis of Candida infections, and T2Bacteria, a blood test for the diagnosis of bacterial infections. The company is also working on developing tests for detecting antibiotic resistance in infections. In the research and development field, T2 Biosystems continuously invests in improving its technologies and products. The company collaborates with universities, research institutions, and other companies to accelerate its research processes and achieve optimal results. This includes collaborations with the Centers for Disease Control and Prevention (CDC) and the United States Department of Defense (DoD). Clinical trials are another focus of T2 Biosystems. The company works with physicians and medical facilities to test and validate its diagnostic products in clinical settings. By collaborating with these institutions, the company gains a better understanding of the clinical effectiveness of its products and technologies and receives feedback from medical professionals. T2 Biosystems sells its products and solutions worldwide through a network of distribution partners and customers. The company also collaborates with hospitals and clinical laboratories to directly sell its technologies and products to healthcare professionals. Overall, T2 Biosystems' business model aims to revolutionize diagnostics in the field of infections. Through the development of innovative diagnostic technologies and collaboration with medical professionals, the company aims to achieve faster, more accurate, and more effective diagnostics, leading to improved patient care.

What is the T2 Biosystems dividend?

T2 Biosystems pays a dividend of 0 USD distributed over payouts per year.

How often does T2 Biosystems pay dividends?

The dividend cannot currently be calculated for T2 Biosystems or the company does not pay out a dividend.

What is the T2 Biosystems ISIN?

The ISIN of T2 Biosystems is US89853L1044.

What is the T2 Biosystems WKN?

The WKN of T2 Biosystems is A119H3.

What is the T2 Biosystems ticker?

The ticker of T2 Biosystems is TTOO.

How much dividend does T2 Biosystems pay?

Over the past 12 months, T2 Biosystems paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, T2 Biosystems is expected to pay a dividend of 0 USD.

What is the dividend yield of T2 Biosystems?

The current dividend yield of T2 Biosystems is .

When does T2 Biosystems pay dividends?

T2 Biosystems pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of T2 Biosystems?

T2 Biosystems paid dividends every year for the past 0 years.

What is the dividend of T2 Biosystems?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is T2 Biosystems located?

T2 Biosystems is assigned to the 'Health' sector.

Wann musste ich die Aktien von T2 Biosystems kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of T2 Biosystems from 10/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/5/2024.

When did T2 Biosystems pay the last dividend?

The last dividend was paid out on 10/5/2024.

What was the dividend of T2 Biosystems in the year 2023?

In the year 2023, T2 Biosystems distributed 0 USD as dividends.

In which currency does T2 Biosystems pay out the dividend?

The dividends of T2 Biosystems are distributed in USD.

All fundamentals about T2 Biosystems

Our stock analysis for T2 Biosystems Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of T2 Biosystems Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.